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Abstract
Coronary artery disease (CAD) is a leading cause of 
death and disability worldwide. Cardiovascular magnetic 
resonance (CMR) is established in clinical practice 
guidelines with a growing evidence base supporting its 
use to aid the diagnosis and management of patients with 
suspected or established CAD. CMR is a multi-parametric 
imaging modality that yields high spatial resolution images 
that can be acquired in any plane for the assessment of 
global and regional cardiac function, myocardial perfusion 
and viability, tissue characterisation and coronary artery 
anatomy, all within a single study protocol and without 
exposure to ionising radiation. Advances in technology 
and acquisition techniques continue to progress the utility 
of CMR across a wide spectrum of cardiovascular disease, 
and the publication of large scale clinical trials continues 
to strengthen the role of CMR in daily cardiology practice. 
This article aims to review current practice and explore 
the future directions of multi-parametric CMR imaging in 
the investigation of stable CAD.
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Core tip: Coronary artery disease (CAD) is a leading cause 
of death worldwide. Cardiovascular magnetic resonance 
(CMR) is established in clinical practice guidelines with 
a growing evidence base supporting its use to aid dia-
gnosis and management of patients with suspected or 
established CAD. CMR is a multi-parametric imaging 
modality that yields high spatial resolution images that 
can be acquired in any plane for assessment of global 
and regional cardiac function, myocardial perfusion and 
viability, tissue characterisation and coronary artery an-
atomy, all within a single study protocol and without 
exposure to ionising radiation.
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INTRODUCTION
Coronary artery disease (CAD) is a leading cause of death 
and disability worldwide[1]. Despite major advances in 
the treatment of CAD resulting in significantly decreased 
mortality rates, CAD remains the single most common 
cause of death in the European Union, leading to 19% 
of deaths in men and 20% of deaths in women[2]; in the 
United States, CAD causes 1 in every 7 deaths, accounting 
for 370213 deaths in 2013[3]. The economic health bur­
den of CAD is substantial with an estimated cost of CAD 
management at €60 billion in the European Union[4], 
and $182 billion in the United States[3]. Cardiovascular 
medicine benefits from a myriad of diagnostic methods 
that can guide intervention and clinical decision­making. 
Invasive coronary X­ray angiography delineates coronary 
anatomy in patients presenting with stable chest pain, 
however there is a low yield of obstructive CAD in those 
referred, and there are associated risks, albeit low, from 
major complications and ionising radiation[5]. Furthermore 
unless measurement of fractional flow reserve (FFR) is 
performed, routine coronary angiography does not give 
information on ischaemia burden, which according to 
current guidelines, is required to guide revascularisation 
decisions. Non­invasive functional imaging modalities 
such as single­photon emission computed tomography 
(SPECT), dobutamine stress echocardiography (DSE), 
cardiovascular magnetic resonance (CMR) or positron 
emission tomography (PET) are used to diagnose CAD, 
guide clinical decision making and confer prognostic 
information and consequently are well established for 
these roles in clinical practice guidelines[6,7].
CMR is a unique multi­parametric imaging modality 
producing high spatial resolution images that can be 
acquired in any plane for the assessment of global and 
regional cardiac function, myocardial perfusion and 
viability, tissue characterisation and proximal coronary 
artery anatomy, all within a single study and without 
exposure to ionising radiation (Figure 1). Historically, long 
scanning times, limited scanner availability and narrow 
bore sizes restricted the use of CMR, but these issues 
have been largely resolved, such that CMR has become a 
first line investigation for suspected stable angina in many 
centres in the United Kingdom and Europe. Consequently 
CMR is part of international clinical practice guidelines 
for the assessment of known and unknown stable CAD 
and for the identification of those who may benefit from 
revascularisation[6-9]. This review aims to focus on the 
current utility of CMR for the diagnosis of suspected stable 
CAD and potential future developments and applications 
of CMR in this role.
CMR IN STABLE CAD
A CMR protocol for the investigation of stable CAD will 
typically take between 30-60 min and involves the 
acquisition of cine images in multiple planes for the 
assessment of left ventricular function and volumes, 
stress and rest myocardial perfusion imaging and late 
gadolinium enhancement (LGE) imaging for the ass­
essment of myocardial viability and scar quantification 
(Figure 2). 
CMR is the reference standard non­invasive technique 
for the measurement of left ventricular (LV) and right 
ventricular (RV) volumes, and ejection fraction, with high 
intra­ and inter­observer reproducibility[10,11]. Steady state 
free precession cine imaging is typically performed for the 
assessment of LV function to enable visual assessment of 
global and regional myocardial function in a similar manner 
to echocardiography; however there are no limitations due 
to poor acoustic windows or large body habitus degrading 
image quality. CMR volumetric analysis is performed by 
acquiring a stack of contiguous breath held cine images 
from the base of the heart to the apex; the endocardial 
and epicardial borders are subsequently contoured 
giving mass, volumes and function. Thus CMR provides 
a true 3D analysis of LV and RV function unlike 2D 
echocardiography that relies on geometric assumptions for 
volumetric calculations. Furthermore specific myocardial 
tagging pulse sequences can be performed that enable 
more detailed assessment of intra­myocardial mechanics 
beyond ejection fraction, including torsion, twist, strain 
and strain rates[12]. Additionally, feature tracking is a novel 
post­processing method of quantitatively assessing strain 
and strain rate using standard cine images without having 
to acquire further imaging sequences as is the case with 
standard CMR tissue tagging[12,13]. 
DIAGNOSIS OF CAD
Ischaemia detection by CMR is performed using either 
vasodilator or inotropic stress. Ischaemia detection by CMR 
is recommended as a first line strategy for investigating 
suspected angina in patients with an intermediate pre­test 
likelihood of CAD in both the current European Society 
of Cardiology (ESC) and National Institute for Health and 
Care Excellence (NICE) guidelines (Table 1)[6,14], whilst the 
United States guidelines are more conservative and give 
a grade IIa recommendation for stress perfusion CMR in 
patients with uninterpretable ECGs or unable to exercise[7]. 
STRESS PERFUSION CMR
Stress perfusion CMR requires the induction of hyperaemia 
by a vasodilating agent, and then observation of the passage 
of a gadolinium based contrast agent (GBCA) through the 
myocardium to identify perfusion defects. Typically the 
vasodilating agent used is adenosine though regadenason 
and less commonly dipyridamole and nicorandil are also 
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used. Adenosine produces vasodilatation in most vascular 
beds, including the coronary circulation, via A2A and A2B 
receptors[15]. Adenosine is given as an intravenous infusion 
typically at a rate of 140 mcg/kg per minute, though this 
can be increased if there is no haemodynamic response; 
the main side effects of adenosine are transient heart block, 
and bronchospasm can be caused in those with reversible 
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airways disease[15]. Regadenason is a new selective A2A 
adenosine receptor agonist that is given via an intravenous 
bolus, has less respiratory side effects than adenosine, and 
has recently been approved by both the FDA and in Europe 
for this indication[16,17]. The coronary micro­vasculature can 
dilate up to 4 or 5 times from the resting state to ensure 
adequate tissue perfusion for example during exercise. 
Cine imaging Cine imaging
EGE imaging LGE imaging
Perfusion imaging
MR angiography
A B C
D E F
Figure 1  Cardiovascular magnetic resonance imaging techniques. A and B show short axis and 4 chamber cine images respectively for anatomical and 
functional assessment; C shows stress perfusion with a septal perfusion defect (arrow); D shows early gadolinium enhancement imaging with a large apical thrombus 
(arrow); E is late gadolinium enhanced imaging with a transmural inferior infarction (arrows); F is 3D whole heart magnetic resonance angiography. LGE: Late 
gadolinium enhancement; EGE: Early gadolinium enhancement.
Localisers                     Stress perfusion                     Function                      Rest perfusion                Early gadolinium                Late gadolinium
Localisers                         Function                             Incremental Dobutamine stress                         Early gadolinium                Late gadolinium
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Figure 2  Cardiovascular magnetic resonance multi-parametric protocols for the investigation of suspected coronary artery disease. A shows a typical multi-
parametric cardiovascular magnetic resonance protocol for the investigation of stable coronary artery disease with adenosine stress perfusion; and B with incremental 
dose dobutamine stress.
A
B
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(n = 515) also confirmed CMR’s superior sensitivity 
compared to SPECT (67% vs 59%, P = 0.024) but 
with a lower specificity (61% vs 72%, P = 0.038)[22]; 
however unlike CE­MARC only the stress/rest perfusion 
component of the CMR protocol was analysed. CE­MARC 
included analysis of LGE for scar detection, cine imaging 
for regional ventricular function and magnetic resonance 
angiography (MRA) for coronary artery anatomy, and a 
subsequent sub­analysis of CE­MARC demonstrated the 
additive diagnostic accuracy of the summation of these 
components of the multi­parametric protocol[23].
Stress perfusion CMR has also been validated against 
FFR in a recent meta­analysis with a pooled sensitivity 
and specificity of 0.90 (95%CI: 0.86-0.93) and 0.87 
(95%CI: 0.82­0.90) at the patient level and 0.89 (95%CI: 
0.83-0.92) and 0.86 (95%CI: 0.77-0.92) at the coronary 
artery and territory levels[24]. Furthermore CMR stress 
perfusion had comparable sensitivity and specificity to 
cardiac CT and PET in a recent meta­analysis of non­
invasive imaging modalities, and was superior to both 
SPECT and DSE when using FFR as the reference stan­
dard[25]. Most trials thus far have excluded patients 
with arrhythmia amid concerns regarding ECG gating, 
however the diagnostic accuracy of stress perfusion 
CMR remains high in suspected CAD patients with AF or 
However the microvasculature distal to a stenosed coronary 
artery is already near­maximally vasodilated at rest and 
consequently when hyperaemia is provoked a coronary 
steal effect is caused. GBCAs increase the signal intensity 
in T1 weighted images and the passage of GBCAs through 
the myocardium causes healthy myocardium to become 
brighter while regions of hypoperfusion (“ischaemia”) 
remain dark (Figure 3). 
The diagnostic accuracy of stress perfusion CMR for 
the detection of CAD is well validated. A meta­analysis 
of 37 studies demonstrated a combined sensitivity of 
89% (95%CI: 88%-91%) and specificity of 76% 
(95%CI: 73%­78%) for perfusion CMR for the diagnosis 
of CAD[18]. The CE­MARC study (n = 752), the largest 
prospective randomised single­centre trial of CMR in this 
context showed superiority of perfusion CMR over SPECT, 
with a higher sensitivity (87% vs 67%, P < 0.0001) and 
negative predictive value (91% vs 79%, P < 0.0001) 
but similar specificity (83% vs 83% P = 0.916) and 
positive predictive values (77% vs 71%, P = 0.061)[19,20]. 
Furthermore in a pre-specified gender sub analysis of CE-
MARC, CMR showed similar sensitivity for CAD detection 
in both males and females, whilst SPECT had significantly 
lower sensitivity in females compared to males[21].
The multi­centre, multi­vendor MR­IMPACT Ⅱ trial 
Table 1  European Society of Cardiology and American College of Cardiology Foundation/American Heart Association Recommendations 
for cardiovascular magnetic resonance in stable coronary artery disease
ESC guidelines
Suspected/stable coronary artery disease[6]
In patients with suspected stable coronary artery disease and pretest probability of 15%-85% stress imaging is preferred as the initial test 
option if local expertise and availability permit
Class Ⅰ
An imaging stress test is recommended in patients with resting ECG abnormalities, which prevent accurate interpretation of ECG changes 
during stress
Class Ⅰ
CMR should be considered in symptomatic patients with prior revascularisation (PCI or CABG) Class Ⅱa
Risk stratification is recommended based on clinical assessment and the results of the stress test initially employed for making a diagnosis 
of stable coronary artery disease
Class Ⅰ
CMR is recommended in the presence of recurrent or new symptoms once instability has been ruled out Class Ⅰ
In symptomatic patients with revascularised stable coronary artery disease, CMR is indicated rather than stress ECG Class Ⅰ
CMR is recommended for risk stratification in patients with known stable coronary artery disease and a deterioration in symptoms if the 
site and extent of ischemia would influence clinical decision making
Recommendations for imaging to determine ischemia to plan revascularisation[6,144] 
Class Ⅰ
An imaging stress test should be considered to assess the functional severity of intermediate lesions on coronary arteriography Class Ⅱa
To achieve a prognostic benefit by revascularisation in patients with coronary artery disease, ischemia has to be documented by non-
invasive imaging
Class Ⅰ
Following MI with multivessel disease, or in whom revascularisation of other vessels is considered, CMR for ischaemia and viability is 
indicated before or after discharge
Class Ⅰ
Heart failure[8]
CMR should be considered in patients with HF thought to have CAD, and who are considered suitable for coronary revascularization, to 
determine whether there is reversible myocardial ischaemia and viable myocardium
Class Ⅱa
AHA guidelines
Diagnosis and management of stable coronary artery disease[7]
CMR can be used for patients with an intermediate (10%-90%) to high (> 90%) pretest probability of obstructive IHD who have an 
uninterpretable ECG and at least moderate physical functioning or no disabling comorbidity
Class Ⅱa
CMR is reasonable for patients with an intermediate to high pretest probability of IHD who are incapable of at least moderate physical 
functioning or have disabling comorbidity
Class Ⅱa
Pharmacological stress CMR is reasonable for risk assessment in patients with SIHD who are unable to exercise to an adequate workload 
regardless of interpretability of ECG
Class Ⅱa
CMR is reasonable in patients with known SIHD who have new or worsening symptoms (not unstable) and who are incapable of at least 
moderate physical functioning or have disabling comorbidity
Class Ⅱa
ESC: European Society of Cardiology; CMR: Cardiovascular magnetic resonance; ECG: Electrocardiogram; CABG: Coronary artery bypass graft; PCI: 
Percutaneous coronary intervention; AHA: American Heart Association; IHD: Ischemic heart disease; SIHD: Stable ischemic heart disease.
Foley JRJ et al . CMR in stable coronary disease
96 February 26, 2017|Volume 9|Issue 2|WJC|www.wjgnet.com
resolution of 2­3 mm. Developments in CMR technology 
however now allow faster scan speeds; these novel 
acquisition techniques allow accelerated data acquisition 
based on spatio­temporal undersampling (k-t SENSE or 
k-t BLAST and highly constrained back projection HYPR, 
compressed sensing and others)[33]. These faster data 
acquisition techniques have been applied to achieve 
in­plane spatial resolution < 2 mm or full­coverage of 
the LV using 3D whole­heart perfusion imaging. High 
spatial-resolution imaging offers benefits by significantly 
reducing dark rim artefacts, as these are directly 
proportional to voxel size[34]. Moreover there is improved 
ability to detect sub­endocardial ischaemia which is 
critical in multi­vessel disease where there is a lack of 
reference healthy myocardium for comparison[35,36]. High 
spatial­resolution perfusion CMR has been validated 
at both 1.5T and 3.0T against quantitative coronary 
angiography (QCA) with improved diagnostic accuracy 
at both field strengths compared to standard resolution 
perfusion imaging[27,36,37]. Furthermore validation against 
FFR gave sensitivity and specificity to detect stenoses at 
a threshold of FFR < 0.75 of 0.82 and 0.94 (P < 0.0001) 
respectively, and an area under the curve of 0.92 (P < 
0.0001)[38].
Conventional stress perfusion CMR is typically acquired 
in 3 short­axis slices, and thus unlike SPECT does not truly 
calculate global ischaemia burden. Accelerated acquisition 
techniques can also be employed to achieve full LV 
coverage using a 3D whole­heart single shot acquisition. 
frequent ectopy (sensitivity 80%, specificity 74%)[26]. 
1.5T VS 3.0T FIELD STRENGTH
Although 1.5T is remains the standard field strength 
used in clinical CMR, imaging at a higher field strength 
of 3.0T offers increased signal to noise and contrast to 
noise ratios thereby giving improved spatial and temporal 
enhancement[27]. Consequently the diagnostic accuracy 
of perfusion imaging at 3.0T may be improved, and 
in a small direct comparison of CMR perfusion at 1.5T, 
3.0T (n = 61) showed greater diagnostic accuracy in 
both single vessel (AUC: 0.89 vs 0.70; P < 0.05) and 
multi­vessel disease (AUC: 0.95 vs 0.82, P < 0.05)[28]. 
Furthermore, 3.0T has been compared to 1.5T using 
FFR as reference standard, corroborating it’s superior 
diagnostic accuracy[29,30]. The higher 3.0T field strength 
does however pose challenges with greater field 
inhomogeneity, susceptibility artefacts and higher local 
energy deposition. Also, many implants deemed “MR 
compatible” at 1.5T cannot be scanned at 3.0T[31]. These 
issues are however being overcome with improved 
technology and the use of multi­transmit radiofrequency 
CMR techniques improving field homogeneity[32].
IMPROVING PERFUSION IMAGING
Currently typical CMR perfusion imaging acquires 3 short 
axis slices of the left ventricle with an in­plane spatial 
A C E
B D F
Figure 3  Cardiovascular magnetic resonance perfusion techniques. A is a high spatial resolution k-t BLAST stress perfusion CMR study at 3.0T showing an 
antero-septal perfusion defect with corresponding left anterior descending lesion at angiography in B; C shows a transmural lateral perfusion defect at standard 
resolution at 1.5T with corresponding circumflex lesion in D; E shows a transmural inferior perfusion defect at standard resolution at 1.5T with corresponding right 
coronary artery lesion in F. BLAST: Broad-use linear acquisition speed-up technique; CMR: Cardiovascular magnetic resonance.
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a risk of nephrogenic systemic fibrosis[53]. In those 
patients unable to have GBCAs inotropic stress CMR is an 
alternative. Inotropic stress CMR is typically performed 
with dobutamine in a similar manner to DSE with in­
ducible regional wall motion abnormalities identified in 
territories supplied by a stenosed coronary artery at 
peak stress. Unlike DSE however, DSMR’s accuracy is not 
limited by body habitus or in those with poor acoustic 
windows and in a single centre study DSMR was shown 
to have significantly greater diagnostic performance to 
DSE in this context[54]. However echocardiography in 
this study was performed without harmonic imaging and 
contrast agents, so that the performance of DSE is likely 
to be underreported compared with contemporaneous 
methods. DSMR has a comparable safety profile to DSE 
with an event rate of 0.1% for sustained VT and 0.4% 
for non-sustained VT, and 1.6% for atrial fibrillation; 
patients thus require close monitoring during scanning 
and resuscitation equipment needs to be available[55]. 
DSMR has been shown to have high diagnostic accuracy 
for the detection of CAD with one meta­analysis of 14 
trials showing a pooled sensitivity of 0.83 (95%CI: 
0.79-0.88) and specificity of 0.86 (95%CI: 0.81-0.91)[56]; 
furthermore a single centre trial of DSMR vs perfusion 
CMR showed similar diagnostic accuracy[57]. First­
pass perfusion can be performed additionally at peak 
dobutamine stress to provide incremental diagnostic 
accuracy[58], and can be a useful adjunct in challenging 
patient groups such as those with pre­existing wall 
motion abnormalities or dyssynchrony from left bundle 
branch block[59]. 
Exercise is commonly used rather than pharmacological 
agents as the stressor in echocardiography, and gives 
useful prognostic information such as workload in 
metabolic equivalent (METs) in addition to ischaemia 
testing[60,61]. CMR is limited in this respect due to the need 
for supine scanning and consistent positioning within 
the scanner. Recent studies however have assessed the 
feasibility of exercise stress CMR and showed comparable 
accuracy to echocardiography, though it has yet to reach 
mainstream clinical use[62,63]. Promising developments are 
“steppers” and cycle ergometers that can attach directly 
to the MRI scanner, and thereby eliminate the need to 
transfer the patient from the exercise equipment into the 
scanner[64,65].
Prognosis from stress CMR
Both perfusion CMR and DSMR provide excellent pro­
gnostic information, and this has recently been shown in 
two large meta­analyses. One meta­analysis of 14 studies 
including 12178 patients showed that a negative stress 
CMR was associated with a 1.03% annualised event rate, 
comparable to the normal population[66]. A further meta­
analysis of 19 studies including 11636 patients showed 
a similar annualised event rate of 0.8% for a negative 
stress CMR over a mean follow up of 32 mo[67]. In a large 
prospective study of 1229 patients undergoing adenosine 
stress with a mean follow­up period of 4.2 ± 2.1 years, 
patients with reversible perfusion deficits had a 3­fold 
Such 3D acquisitions can overcome the assumptions 
made about “missing” myocardium between the slices 
from conventional 2D multi­slice perfusion imaging. 
Two studies have validated the feasibility and diagnostic 
accuracy of 3D stress perfusion CMR against FFR; at 1.5T 
3D perfusion demonstrated a sensitivity, specificity and 
diagnostic accuracy of 90%, 82% and 87% respectively 
and 91%, 90% and 91% respectively at 3.0T[39,40]. 
Furthermore in a recent multicentre trial of 3D stress 
perfusion at 3.0T, sensitivity and specificity were 84.7% 
and 90.8% relative to the FFR reference[41]. The main 
motivation for 3D perfusion is to give a more accurate 
quantification of total myocardial ischaemia burden; 
evidence from SPECT suggests a prognostic benefit for 
revascularisation in those with an ischaemia burden > 
10%, with an ischaemia burden of 10% conferring a 
risk of approximately 5% for death or MI per year[42,43]. 
Ischaemia burden as measured by 3D stress perfusion 
CMR has been compared to SPECT and showed good 
correlation (rs = 0.70, P < 0.001)[44]. Intriguingly a recent 
pilot study compared ischaemia burden by high­resolution 
perfusion (using 3 short axis slices) and 3D perfusion 
imaging (providing whole heart coverage) suggesting that 
there was also a good correlation between the techniques (r 
= 0.72; P = 0.001), and that therefore the two methods 
are potentially interchangeable[45].
QUANTITATIVE PERFUSION
CMR stress perfusion studies are normally reported in a 
qualitative manner; however this can prove challenging in 
diffuse or multi­vessel disease where there is no healthy 
reference myocardium to use as a visual comparator. 
These situations can introduce subjectivity into the analysis 
and consequently quantitative measurement techniques 
have been developed to provide an objective assessment 
of myocardial blood flow. A number of different methods 
of quantitative analysis have been assessed with the Fermi 
deconvolution method showing most accuracy when 
compared to microspheres in an explanted porcine model 
at 1.5T and mice at 3.0T[46,47], and when compared to 
SPECT and with QCA[48]. When compared to angiography 
with FFR, an MPR threshold of 1.58 detected a stenosis 
with an FFR < 0.75 with a sensitivity of 0.80, specificity 
of 0.89 (P < 0.0001), and area under the curve of 0.89 
(P < 0.0001)[38]. Myocardial perfusion reserve derived 
from quantitative CMR perfusion has also shown good 
correlation to PET imaging, the imaging modality that is 
widely regarded as the reference standard non­invasive 
measure of myocardial blood flow[49,50]. Currently, time 
consuming post­processing has limited quantitative per­
fusion methods to a research tool, but automated me­
thods are being developed that may potentially overcome 
this[51].
DOBUTAMINE STRESS CMR
GBCAs have an excellent safety profile[52], but in patients 
with poor renal clearance (e.g., on dialysis) there is 
Foley JRJ et al . CMR in stable coronary disease
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provide an alternative for patients that struggle to breath­
hold[76,77]. 
VIABILITY ASSESSMENT
CMR viability assessment using LGE enables the accurate 
detection, and extent and trans­murality of previous 
myocardial infarction to be determined, and identifies regions 
with potential to recover function following revascularisation. 
Hibernating myocardium is dysfunctional myocardium 
that has been down­regulated through a process of 
chronic/repetitive ischaemia and which has the potential 
for functional recovery when blood flow is restored. LGE 
imaging detects replacement of normal viable myocytes 
by focal necrosis or fibrosis with high spatial resolution, and 
has excellent correlation to histopathology[73]. Furthermore 
the degree of transmural extent of hyper­enhancement 
on LGE imaging has a direct association to the potential for 
functional recovery following revascularisation; Kim et al[78] 
demonstrated that segments with less than 25% hyper­
enhancement were most likely to attain functional recovery 
whilst segments with over 75% hyper­enhancement were 
unlikely to improve, notably this was irrespective of whether 
the region was initially hypokinetic, dyskinetic or akinetic. 
A meta­analysis of 331 patients using 50% trans­murality 
of hyper­enhancement reported a sensitivity of 95% 
(95%CI: 93%-97%) and specificity of 51% (40%-62%) 
for predicting functional recovery[79].
CMR viability assessment is not however limited to 
just LGE imaging; whilst LGE identifies the transmural 
extent of scarring, the use of low­dose dobutamine 
(LDD) identifies the contractile reserve. Myocardium is 
considered viable if there is a 2 mm or more increase 
in systolic wall thickening within a segment following 
administration of LDD (5­10 mcg/kg per minute)[80]. While 
scar burden on LGE has been shown to be most sensitive 
method for assessment for functional recovery compared 
to LDD and diastolic wall thickness[81], LDD CMR offers 
higher specificity and PPV for prediction of functional 
recovery (91% and 93%, respectively)[79]. Consequently a 
stepwise approach utilising LGE first followed by LDD if the 
trans­mural extent of LGE in the territory of the diseased 
coronary is between 1%­50% has been proposed[82]. 
Recently both tissue tagging and feature tracking have 
been used to give quantitative viability assessment with 
LDD and have been suggested as possible methods to 
reduce reliance on operator experience in what is currently 
a qualitative method of assessment[83­85].
LGE imaging has a grade A recommendation to deter­
mine myocardial viability prior to revascularisation in 
the ACCF/AHA/SCMR appropriate use guidelines[86], 
though viability assessment by LGE is currently not 
recommended for this indication in ESC or US practice 
guidelines for management of stable CAD or coronary 
revascularisation[6,7,9,87]. The utility of viability assessment 
has been questioned recently following the results of 
the STICH trial and the subsequently published viability 
sub­study that showed no mortality benefit from re­
increased risk of major adverse cardiovascular events, 
with significantly more cardiac deaths (P < 0.0001) and 
nonfatal myocardial infarctions (P < 0.001)[68]. Similarly 
the data from DSMR mirrors the results of first­pass 
perfusion CMR with a negative study conferring an equally 
low annual event rate of 1.3%[66,69]. Recently the five­
year outcome data from CE­MARC were published with 
prognostic data for both CMR and SPECT in the same 
patient population. The analysis showed that although an 
abnormal result from both tests was a strong indicator 
of future major adverse cardiovascular events (MACE), 
CMR was superior at predicting time to MACE in this 
population[70]. Furthermore CMR remained the only 
independent predictor of outcome after adjustment for 
major cardiovascular risk factors, stratification for initial 
patient treatment and coronary angiographic findings[70]. 
These findings likely reflect CMR’s overall greater diag­
nostic accuracy, combined with CMR’s higher spatial 
resolution enabling greater identification of subendocardial 
scar compared to SPECT[71]; a feature known to confer 
prognostic significance beyond ejection fraction, and 
clinical or angiographic features[72].
EARLY AND LATE GADOLINIUM 
ENHANCEMENT IMAGING
GBCAs have a large molecular weight and cannot 
penetrate an intact cell membrane; consequently GBCAs 
are constrained to the extracellular space. In healthy 
myocardium the extracellular space is limited and contrast 
enters and clears rapidly. The extracellular space in in­
farcted myocardium however is substantially increased 
compared to normal myocardium and is less vascular. 
Thus in chronic myocardial infarction scar tissue composed 
of a matrix of collagen fibres has significantly increased 
extracellular space, leading to GBCA accumulation (slow 
washout), whilst in acute infarction GBCAs passively diffuse 
across disrupted myocardial cell membranes and into the 
intracellular space (greater volume of distribution)[73]. Thus 
both acute and chronic myocardial infarction retain more 
GBCAs. Imaged with T1 sensitive acquisition methods, 
this results in a higher signal. 
Early gadolinium enhancement imaging is performed 
immediately following contrast administration; this allows 
mainly the visualisation of ventricular thrombi that appear 
“dark/black” due to a lack of contrast uptake as they 
are non­vascular (Figure 4). CMR has been shown to be 
superior to both trans­thoracic echocardiography and 
trans-oesophageal echocardiography for the identification 
of ventricular thrombi[74,75]. LGE imaging is performed 
between 10­20 min after contrast administration, an 
appropriate inversion time is set to null the normal myo­
cardium and the areas where gadolinium is retained 
enhances (Figure 4). Typically a stack of short axis slices, 
a 4­chamber view and VLA are acquired. Alternatively, 
3D LGE CMR imaging enables whole heart quantification 
of scar burden to be acquired in a shorter time period 
(although with a reduction in image quality), which may 
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risk of both mortality and MACE[72,98]. 
The extent of scar burden by LGE in patients with 
ischaemic heart disease has also been identified in a 
number of studies to be an independent predictor of 
ventricular arrhythmias in patients with internal cardiac 
defibrillators (ICD)[99­101], and a recent meta­analysis of 
1105 patients with ICDs determined that the extent of 
LGE was predictive of ventricular arrhythmia whilst LVEF 
was not[102]. Additionally in a high risk cohort of patients 
with a mean LVEF of 35% being considered for ICD 
implantation, LGE demonstrated that significant scarring 
(> 5% LV) in patients with LVEF > 30%, conferred a risk 
similar to those with LVEF ≤ 30%[103]. Equally, in patients 
with LVEF ≤ 30%, minimal or no scar burden established 
a lower risk cohort similar to those with LVEF > 30%[103]. 
Other studies have identified the presence of a “grey 
zone” on LGE imaging, a heterogeneous region of viable 
and non­viable myocardium at the infarct periphery, as 
predictive of VT[104,105]. 
LGE and quantification of scar burden has also 
been used to predict responsiveness to cardiac resyn­
chronization therapy (CRT)[106], and identification of 
scarring in the pacing region of the LV lead has been 
associated with non­response to device therapy[107,108]. In 
a similar method to imaging the coronary artery anatomy, 
coronary venous anatomy can be reliably demonstrated 
using GBCAs, which can potentially aid planning of device 
implantation[109]. The combination of coronary venous 
imaging, assessment of ventricular function and LGE 
may be a useful adjunct in the management of patients 
with ischaemic cardiomyopathy being considered for 
CRT, as well as risk stratifying those being considered for 
vascularisation following viability assessment[88,89]. This 
is contrary to prior observational data in large meta­
analyses including over 3000 patients with viability; 
revascularisation was associated with 79.6% reduction 
in annual mortality (P < 0.0001) compared with medical 
treatment[90,91] and presence of dysfunctional viable 
myocardium by LGE­CMR without revascularisation is 
an independent predictor of mortality in patients with 
ischemic LV dysfunction[92]. Questions have been asked 
however whether the STICH sub­study results would 
have been different if CMR had been used rather than 
SPECT, and consequently in Europe the third highest 
indication for CMR remains the assessment of viability[93].
SCAR BEYOND VIABILITY ASSESSMENT
In addition to identifying viable myocardium, the pre­
sence and extent of LGE provides valuable prognostic 
information, and the extent of scar burden by LGE is 
readily quantified and reproducible on CMR[94]. Impairment 
of left ventricular ejection fraction is well recognized as 
an independent risk factor in those with coronary artery 
disease[8,95]; LGE can provide additive prognostication 
in these patients and a recent study of 1560 patients 
established that the presence of scar by LGE irrespective 
of LVEF identified those at risk of increased mortality[96]. 
Furthermore a meta­analysis showed that the presence 
of LGE increases the risk of death by 4.77% and MACE 
by 3.9% and that each gram of scar measured by LGE 
increased the hazards of death and MACE by 4% and 5%, 
respectively[97]. Additionally the identification of previously 
unrecognized MI by LGE confers a significantly increased 
Figure 4  Early and late gadolinium enhancement. A and B show a lateral sub-endocardial infarction on short axis and 4 chamber LGE respectively; C and D 
show a full thickness inferior infarction on LGE imaging on short axis and VLA respectively; E and F show EGE and LGE imaging respectively of a full thickness 
apical infarction with an apical thrombus appearing black (highlighted by red arrow); G shows an extensive acute antero-apical infarction with a core of microvascular 
obstruction visible within the hyperenhancement on EGE (red arrow); H shows an acute inferior wall infarction with MVO and extension into the right ventricle on LGE 
(red arrow) imaging. LGE: Late gadolinium enhancement; EGE: Early gadolinium enhancement; MVO: Mitral orifice.
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unnecessary angiography at 12 mo compared to routine 
guideline directed care[119].
Contemporary registry data from the United States 
suggests roughly 12%-26% of elective PCI are deemed 
inappropriate with considerable variation in practice 
between sites[120,121]. Both FAME and DEFER showed 
improved outcomes using FFR guided revascularisation 
based on ischaemia detection, compared to reliance on 
visual assessment at angiography[122,123]. These trials 
would suggest that a better way of selecting patients prior 
to invasive revascularisation procedures is required. CMR 
offers a non­invasive ischaemia assessment and the MR­
INFORM trial aims to establish if perfusion CMR could 
act as a non­invasive surrogate to FFR to determine the 
need for revascularisation in patients with stable CAD[124]. 
MR­INFORM is a multi­centre, non­inferiority study com­
paring adenosine perfusion CMR vs angiography with 
FFR measurement to guide revascularisation decisions 
in patients with stable angina and moderate to high 
probability of CAD; the primary endpoint is the occurrence 
of MACE at one year. The trial has completed recruitment 
and is expected to report in 2017. 
The prognostic benefit of revascularisation in stable 
coronary artery disease is a topic of debate; both the 
COURAGE trial and BARI­2D failed to show any prognostic 
benefit of revascularisation over optimal medical therapy 
(OMT) in patients with stable CAD[125,126]. Determination 
of extent of ischaemia in both these 2 trials was however 
limited; in COURAGE only 33% of patients had moderate/
severe ischaemia and moreover around 40% had < 5% 
ischaemia[127]. In both trials however those with a higher 
residual ischaemia burden had a worse prognosis[127­129]. 
The ISCHEMIA trial aims to test the hypothesis that a 
routine invasive strategy with early cardiac catheterisation 
and revascularisation plus OMT is superior to a conser­
vative management strategy of OMT for patients with 
moderate or severe ischemia[42]. The trial aims to recruit 
over 8000 patients worldwide with ischaemia determined 
by non­invasive imaging (CMR, stress echocardiography, 
SPECT) with a primary endpoint of time to cardiovascular 
death or non­fatal myocardial infarction. 
Coronary artery evaluation
Coronary MRA (CMRA) allows the non­invasive ana­
tomical assessment of coronary arteries; currently clinical 
indications are limited to the detection of aberrant origin 
of coronary arteries, coronary ectasia and/or aneurysms 
(class Ⅰ indication) and evaluation of bypass grafts (class 
Ⅱ indication)[130,131]. CMRA for diagnosis of CAD is not 
presently part of routine clinical practice. The initial multi­
centre experience using CMRA in this context showed 
interpretable image quality in 84% of proximal and middle 
coronary artery segments, though with a specificity of 
42%; CMRA did however exclude triple­vessel disease 
and left main coronary artery stenosis with a negative 
predictive value of 100%[132]. Progress in CMRA techniques 
have improved significantly however, and a recent multi-
centre study showed that CMRA at 1.5T detects significant 
defibrillator therapy.
COST EFFECTIVENESS
The economic burden of CAD is enormous with £6.8 
billion spent in 2012 in the United Kingdom; in the United 
States over 15 million people have CAD costing the US 
economy $108.9 billion/year[110,111]. Cost effectiveness 
analyses help to inform optimal management pathways 
in order to maximise health care benefit within the con-
straints of limited resources. In the United States a low 
yield has been reported at diagnostic angiography with 
just over 40% of patients referred having obstructive 
CAD[5]. CMR can act as a potential gatekeeper to invasive 
coronary angiography in order to reduce downstream 
costs as well as reduce risk from unnecessary invasive 
assessments.
Health economic analyses based on the CE­MARC 
dataset identified that despite the higher initial cost 
of CMR to SPECT, the superior diagnostic accuracy of 
CMR lead to an overall greater cost effectiveness in 
models of the United Kingdom, German and Swiss 
healthcare systems[112­114]. A study of 1158 German 
patients being investigated for suspected CAD were 
randomised to either DSMR prior to angiography or direct 
to angiography; DSMR prior to invasive angiography 
led to a saving of 12466€ of hospital costs per life year, 
furthermore this cost saving was maintained through a 
median period of 7.9 years follow­up[115].
In a cost analysis comparing CMR and X­ray angio­
graphy vs angiography and FFR to determine the 
need for revascularisation, CMR and angiography was 
more cost-effective below a CAD prevalence of 62%, 
65%, 83% and 82% for the Swiss, German, United 
Kingdom, and the United States health care systems, 
respectively[116]. These studies confirm that as well as 
the established high diagnostic accuracy, CMR is also a 
financially advantageous investigative strategy in patients 
with CAD. 
RECENTLY PUBLISHED AND FUTURE 
STUDIES
Studies thus far have predominantly focused on the 
diagnostic accuracy of CMR; forthcoming multi­centre 
clinical effectiveness trials are however focused on 
evaluating clinical pathways to improve patient outcomes. 
The recently published CE­MARC 2 trial is a prospective, 
multi­centre, 3­arm parallel group, randomised controlled 
trial comparing multi­parametric CMR vs UK NICE 
CG95 guidance[14] vs AHA/ACCF SPECT appropriate­
use criteria[117] to investigate patients with suspected 
CAD (pre­test likelihood 10%­90%) requiring further 
investigation[118,119]. The primary outcome measure was 
FFR defined unnecessary angiography (FFR > 0.8) with 
the important safety secondary outcome measure of 
MACE at 1 and 3 years. CE­MARC 2 showed overall that 
CMR guided care resulted in significantly reduced rates of 
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nostic accuracy of CMR for the investigation of stable 
coronary artery disease has been confirmed through 
the publication of large­scale clinical trials and meta­
analyses, and CMR is now firmly established in clinical 
practice guidelines. CMR enables assessment of cardiac 
dimensions, function, ischaemia, scar burden and tissue 
viability in a single study without exposure to ionising 
radiation. CMR also offers prognostic information with a 
normal stress CMR associated with a < 1% risk of death 
or MI at 2 years, whilst the presence of LGE confers 
added prognostication above and beyond simple LV 
ejection fraction. New technical developments continue 
apace and ongoing large clinical trials will further clarify 
the role of CMR in routine clinical practice and guide the 
future development of international guidelines.
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